Sorafenib
- Generic Name
- Sorafenib
- Brand Names
- Nexavar, Sorafenib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 284461-73-0
- Unique Ingredient Identifier
- 9ZOQ3TZI87
- Background
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to ...
- Indication
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
- Associated Therapies
- -
Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 14
- Registration Number
- NCT00496756
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor
- Conditions
- Interventions
- First Posted Date
- 2007-07-03
- Last Posted Date
- 2012-10-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 204
- Registration Number
- NCT00495872
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
- Conditions
- Metastatic Head and Neck Squamous Cell CarcinomaMetastatic Squamous Cell Carcinoma of the LarynxMetastatic Squamous Cell Carcinoma of the Oral CavityMetastatic Squamous Cell Carcinoma of the OropharynxRecurrent Oropharyngeal Squamous Cell CarcinomaMetastatic Squamous Cell Carcinoma of the HypopharynxRecurrent Head and Neck Squamous Cell CarcinomaRecurrent Hypopharyngeal Squamous Cell CarcinomaRecurrent Laryngeal Squamous Cell CarcinomaRecurrent Oral Cavity Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2007-06-29
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT00494182
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy
- Conditions
- Interventions
- First Posted Date
- 2007-06-28
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Accelerated Community Oncology Research Network
- Target Recruit Count
- 160
- Registration Number
- NCT00493636
- Locations
- 🇺🇸
Compassionate Cancer Care-Fountain Valley, Fountain Valley, California, United States
🇺🇸Hematology Oncology Associates of New York, East Syracuse, New York, United States
🇺🇸California Cancer Care, Greenbrae, California, United States
Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal
- First Posted Date
- 2007-05-30
- Last Posted Date
- 2015-12-09
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 19
- Registration Number
- NCT00480389
- Locations
- 🇨🇦
Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)
- First Posted Date
- 2007-05-24
- Last Posted Date
- 2011-08-29
- Lead Sponsor
- Mahidol University
- Target Recruit Count
- 15
- Registration Number
- NCT00478114
- Locations
- 🇹🇭
Siriraj Hospital, Department of Medicine, Bangkoknoi, Bangkok, Thailand
Sorafenib With TACE to Treat Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2007-05-24
- Last Posted Date
- 2010-11-02
- Lead Sponsor
- University of Bern
- Target Recruit Count
- 21
- Registration Number
- NCT00478374
- Locations
- 🇨🇭
Inselspital, Bern, Switzerland
Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib
- Conditions
- Interventions
- First Posted Date
- 2007-05-17
- Last Posted Date
- 2013-11-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 512
- Registration Number
- NCT00474786
- Locations
- 🇬🇧
Pfizer Investigational Site, Newcastle upon Tyne, United Kingdom
Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2007-05-17
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 103
- Registration Number
- NCT00474929
- Locations
- 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States
AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib
- Conditions
- Interventions
- First Posted Date
- 2007-04-27
- Last Posted Date
- 2016-03-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 152
- Registration Number
- NCT00467025
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.